Replies to post #175699 on DD Support Board and Research Team

[OMOLIVES]

Well...let's look at your statement here:

So, KODK refused to explain the actions when NYT inquired. The options were granted previously as you mention, but THEN THE AMOUNT WAS GOOSED in May, while KODK was in talks w/ Govt, and then market-moving news appears to have been leaked as well (by whom?), and COMPENSATION COMMITTEE convened a VERY TIMELY MEETING immediately prior to announcement.

extracted: but THEN THE AMOUNT WAS GOOSED in May, while KODK was in talks w/ Govt

It was amended in April..April 9th via proxy..and made definitive at said meeting ... https://www.sec.gov/Archives/edgar/data/31235/000120677420001122/kodk3687481-def14a.htm

proposal 4 .. https://www.sec.gov/Archives/edgar/data/31235/000120677420001122/kodk3687481-def14a.htm#p31 (Company’s common stock as reported on the NYSE on April 1, 2020 was $1.65)

Read the proposal and note the share price and also note that it was the third amendment.

2018 first amendment... https://www.sec.gov/Archives/edgar/data/31235/000120677418001133/kodak3353631-def14a.htm

proposal 3 .. https://www.sec.gov/Archives/edgar/data/31235/000120677418001133/kodak3353631-def14a.htm#proposal3_1 ( Company’s common stock as reported on the NYSE on April 3, 2018 was $4.90)

2019 second amendment .. https://www.sec.gov/Archives/edgar/data/31235/000156459019010423/0001564590-19-010423-index.htm ... EX-10.3 .. https://www.sec.gov/Archives/edgar/data/31235/000156459019010423/kodk-ex103_16.htm


The spokesperson should have just said .."refer to the 2013 Omnibus Incentive Plan and amendments there of" and finally with regards to this portion of your statement...

extracted: Starting in May, Kodak began talks with the Trump administration about manufacturing the ingredients for pharmaceuticals, Mr. Continenza said in a television interview this week.

The proposal was put forth on April 9th. Refer to APPENDIX A 2013 Omnibus Incentive Plan, as Amended and Restated in said filing